Sesen Bio, Inc. (SESN) Analysts See $-0.12 EPS

July 14, 2018 - By Elizabeth Jones

Analysts expect Sesen Bio, Inc. (NASDAQ:SESN) to report $-0.12 EPS on August, 13.They anticipate $0.18 EPS change or 60.00 % from last quarter’s $-0.3 EPS. After having $-0.11 EPS previously, Sesen Bio, Inc.’s analysts see 9.09 % EPS growth. It closed at $2 lastly. It is down 17.57% since July 14, 2017 and is uptrending. It has outperformed by 5.00% the S&P500.

Sesen Bio, Inc., a late-stage clinical company, develops next-generation antibody-drug conjugate therapies for patients with cancer. The company has market cap of $153.00 million. It develops its products based on its Targeted Protein Therapeutics platform. It currently has negative earnings. The company's lead product candidate is Vicinium, a fusion protein that is in Phase III clinical trial for the treatment of high-grade non-muscle invasive bladder cancer.

More news for Sesen Bio, Inc. (NASDAQ:SESN) were recently published by: Seekingalpha.com, which released: “Premarket analyst action – healthcare” on July 09, 2018. Streetinsider.com‘s article titled: “Pre-Open Movers 07/09: (MBVX) (HELE) (GRPN) Higher; (CTIC) (PETS) (PG) Lower (more…)” and published on July 09, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.